FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment

Pallavi Madhiraju- June 4, 2024 0

FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in ... Read More

Innovent Biologics showcases promising preclinical data at AACR 2024

Pallavi Madhiraju- April 8, 2024 0

In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More

FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment

Pallavi Madhiraju- February 18, 2024 0

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

Pallavi Madhiraju- January 28, 2024 0

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Iksuda Therapeutics advances IKS014 in Phase 1 trial following positive initial results

Pallavi Madhiraju- October 24, 2023 0

Iksuda Therapeutics, a clinical-stage biotechnology firm from the UK specializing in innovative antibody drug conjugates (ADCs) for tumor specificity, reported successful completion of the first ... Read More

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

Pallavi Madhiraju- July 11, 2023 0

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More

Biomea Fusion to take BMF-219 into clinical trials for KRAS solid tumors

Pallavi Madhiraju- October 16, 2022 0

Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal ... Read More

Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma

pallavi123- June 23, 2022 0

Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. ... Read More

BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn

pallavi123- June 14, 2022 0

Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More

Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial

pallavi123- January 15, 2022 0

Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 ... Read More

12310 / 26 Posts